Allogene Therapeutics (NASDAQ:ALLO) Hits New 12-Month High – Should You Buy?

10 Apr 2026, 12:20 by Danessa Lincoln · The Markets Daily

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) shares hit a new 52-week high during mid-day trading on Wednesday . The company traded as high as $2.82 and last traded at $2.6750, with a volume of 645742 shares trading hands. The stock had previously closed at $2.62.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ALLO. Wall Street Zen upgraded shares of Allogene Therapeutics from a “sell” rating to a “hold” rating in a report on Sunday, February 22nd. Piper Sandler upped their price objective on shares of Allogene Therapeutics from $7.00 to $8.00 and gave the company an “overweight” rating in a research note on Friday, March 13th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $14.00 price objective on shares of Allogene Therapeutics in a report on Friday, March 13th. Citigroup upgraded Allogene Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Friday, January 9th. Finally, Truist Financial raised Allogene Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $8.56.

Check Out Our Latest Stock Report on ALLO

Allogene Therapeutics Trading Up 7.8%

The business’s fifty day moving average price is $2.25 and its 200 day moving average price is $1.67. The firm has a market capitalization of $709.40 million, a price-to-earnings ratio of -3.34 and a beta of 0.53.

Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($0.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.08. As a group, sell-side analysts forecast that Allogene Therapeutics, Inc. will post -1.28 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Allogene Therapeutics news, SVP Earl Martin Douglas sold 22,900 shares of the company’s stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $1.76, for a total transaction of $40,304.00. Following the completion of the sale, the senior vice president directly owned 564,948 shares of the company’s stock, valued at $994,308.48. This represents a 3.90% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO David D. Chang sold 95,269 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $1.80, for a total value of $171,484.20. Following the sale, the chief executive officer directly owned 5,185,862 shares of the company’s stock, valued at $9,334,551.60. The trade was a 1.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 278,452 shares of company stock worth $534,053. Insiders own 13.20% of the company’s stock.

Hedge Funds Weigh In On Allogene Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. increased its stake in Allogene Therapeutics by 177.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company’s stock valued at $8,547,000 after buying an additional 3,747,397 shares during the period. Kalehua Capital Management LLC purchased a new stake in shares of Allogene Therapeutics in the fourth quarter valued at about $3,488,000. Patient Square Capital LP increased its stake in shares of Allogene Therapeutics by 66.5% during the fourth quarter. Patient Square Capital LP now owns 4,963,756 shares of the company’s stock worth $6,800,000 after acquiring an additional 1,982,360 shares during the period. Millennium Management LLC raised its holdings in Allogene Therapeutics by 125.6% during the third quarter. Millennium Management LLC now owns 3,390,026 shares of the company’s stock worth $4,204,000 after purchasing an additional 1,887,302 shares in the last quarter. Finally, Two Sigma Investments LP lifted its position in Allogene Therapeutics by 109.7% in the third quarter. Two Sigma Investments LP now owns 3,383,644 shares of the company’s stock valued at $4,196,000 after purchasing an additional 1,770,419 shares during the period. 83.63% of the stock is currently owned by hedge funds and other institutional investors.

Allogene Therapeutics Company Profile

(Get Free Report)

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.